All Pharma News
Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update

Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update
GLOBENEWSWIRE
05 Apr 2024
Share Share
Updated Results from Single-Agent Phase 1 of Peptide Drug Conjugate, AVA6000

Updated Results from Single-Agent Phase 1 of Peptide Drug Conjugate, AVA6000
GLOBENEWSWIRE
05 Mar 2024
Share Share
Appointment of Chief Business Officer

Appointment of Chief Business Officer
GLOBENEWSWIRE
19 Dec 2023
Share Share
ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data

ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data
GLOBENEWSWIRE
13 Dec 2023
Share Share
Avacta to present promising new data from Affimer

Avacta to present promising new data from Affimer
GLOBENEWSWIRE
05 Oct 2023
Share Share
Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000

Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000
BUSINESSWIRE
21 Jun 2023
Share Share
Avacta enrolls fifth patient in cohort of AVA6000 phase Ia dose escalation study

Avacta enrolls fifth patient in cohort of AVA6000 phase Ia dose escalation study
PHARMABIZ
08 Apr 2023
Share Share
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Study

Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Study
BUSINESSWIRE
06 Apr 2023
Share Share
Avacta Announces First Patient Dosed in Cohort of AVA6000 PhIa Escalation Study

Avacta Announces First Patient Dosed in Cohort of AVA6000 PhIa Escalation Study
BUSINESSWIRE
05 Apr 2023
Share Share
Avacta Appoints Karen Harrison as Chief Operating Officer

Avacta Appoints Karen Harrison as Chief Operating Officer
BUSINESSWIRE
28 Mar 2023
Share Share